Katalin Erdelyi
Overview
Explore the profile of Katalin Erdelyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borbenyi-Galambos K, Erdelyi K, Ditroi T, Juranyi E, Szanto N, Szatmari R, et al.
Cell Metab
. 2025 Mar;
PMID: 40037361
BRAF V600E-inhibition effectively treats melanoma, but acquired resistance rapidly develops. Protein expression profiles, mitochondrial energetics, metabolomics and fluxomics data in cell line, xenograft, and patient-derived xenograft systems revealed that concerted...
2.
Gall T, Petho D, Erdelyi K, Egri V, Balla J, Nagy A, et al.
Redox Biol
. 2024 Sep;
76:103316.
PMID: 39260060
Neovascularization is implicated in the pathology of retinopathy of prematurity (ROP), diabetic retinopathy (DR), and age-related macular degeneration (AMD), which are the leading causes of blindness worldwide. In our work,...
3.
Borbenyi-Galambos K, Czikora A, Erdelyi K, Nagy P
Curr Opin Chem Biol
. 2024 Feb;
79:102440.
PMID: 38422870
Rewiring the transsulfuration pathway is recognized as a rapid adaptive metabolic response to environmental conditions in cancer cells to support their increased cysteine demand and to produce Reactive Sulfur Species...
4.
Czikora A, Erdelyi K, Ditroi T, Szanto N, Juranyi E, Szanyi S, et al.
Redox Biol
. 2022 Oct;
57:102505.
PMID: 36279629
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all cancer types with a constant rise in global incidence. Therefore, better understanding of PDAC biology, in order to design...
5.
Erdelyi K, Ditroi T, Johansson H, Czikora A, Balog N, Silwal-Pandit L, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(45).
PMID: 34737229
Basal-like breast cancer (BLBC) is the most aggressive subtype of breast tumors with poor prognosis and limited molecular-targeted therapy options. We show that BLBC cells have a high Cys demand...
6.
Mellis A, Misko A, Arjune S, Liang Y, Erdelyi K, Ditroi T, et al.
Redox Biol
. 2020 Dec;
38:101800.
PMID: 33271457
Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency are two rare genetic disorders that are caused by impairment of the mitochondrial enzyme sulfite oxidase. Sulfite oxidase is catalyzing the terminal...
7.
Velasco R, Moore C, Deiratany S, DElia F, Tourteau L, Zuiani C, et al.
Eur J Emerg Med
. 2020 Oct;
28(3):196-201.
PMID: 33079737
Objective: The objective of the study was to assess the variability in the management of paediatric MHT in European emergency departments (EDs). Methods: This was a multicentre retrospective study of...
8.
Trojnar E, Erdelyi K, Matyas C, Zhao S, Paloczi J, Mukhopadhyay P, et al.
Free Radic Biol Med
. 2019 Nov;
152:540-550.
PMID: 31770583
Study Rationale: Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver disease characterized by the rapid decline of kidney function. Herein, we explored the therapeutic potential of targeting the...
9.
Matyas C, Erdelyi K, Trojnar E, Zhao S, Varga Z, Paloczi J, et al.
Hepatology
. 2019 Aug;
71(4):1391-1407.
PMID: 31469200
Background And Aims: Hepatic cardiomyopathy, a special type of heart failure, develops in up to 50% of patients with cirrhosis and is a major determinant of survival. However, there is...
10.
Varga Z, Erdelyi K, Paloczi J, Cinar R, Zsengeller Z, Jourdan T, et al.
Hepatology
. 2018 Apr;
68(4):1519-1533.
PMID: 29631342
Conclusion: We propose that hyperammonemia may contribute to impaired renal arginine metabolism, leading to decreased eNOS activity, impaired microcirculation, tubular cell death, tubulointerstitial nephritis and fibrosis. Genetic deletion of arginase-2...